10X Genomics, Inc.

10X Genomics, Inc., a manufacturer of single-cell and spatial transcriptomics platforms and reagents, operates as a prime contractor supplying advanced genomic analysis instruments, consumables, and bioinformatics software to federal research agencies with no SBA set-asides across its footprint. Headquartered in Pleasanton, California, the company is a for-profit corporation classified under primary NAICS codes 334516 (Analytical Laboratory Instrument Manufacturing), 325414 (Biological Product Manufacturing), and 325413 (In-Vitro Diagnostic Substance Manufacturing), competing exclusively in full-and-open federal procurements.

10X Genomics holds a dominant position within the National Institutes of Health system as a supplier of genomic analysis infrastructure. The company's concrete capability portfolio centers on Chromium and Xenium platforms for single-cell RNA sequencing, single-cell ATAC-seq, multiome analysis, and spatial transcriptomics, along with associated reagent kits, chips, consumables, maintenance agreements, and bioinformatics tools. Representative work includes a $7 million indefinite delivery contract with the National Institute on Aging (awarded July 2024, running through July 2029) for optimization slides, reagent kits, and reagent delivery methods; an $800,000 blanket purchase agreement with Veterans Integrated Service Network 1 (awarded May 2024, through May 2027) for Chromium system reagents; and specific delivery orders such as a $249,999 order from NIAID for next-generation sequencing reagents (September 2025), a $897,016.50 order from NIA for Chromium consumables (September 2024), and a $104,650 purchase order from the Army Materiel Command for a ChromiumX automated sequencing library generator (August 2025).

Customer concentration reflects heavy NIH dependence. The National Institute on Aging leads both by award count and dollar value, with 168 awards totaling $19.9 million in combined potential value; the National Institute of Allergy and Infectious Diseases ranks highest by award count with 319 awards worth $14.5 million combined. The NIH Office of Logistics and Acquisition Operations accounts for $11.3 million across 31 awards. Together, these three entities and the National Institute on Drug Abuse and National Heart, Lung, and Blood Institute (each with $3+ million in value) anchor 66 percent of the company's combined potential value. The concentration is acute: the top five customers represent only 58 percent of award count but control 66 percent of dollars, indicating larger per-order values at institutional purchasers like NIA and NIAID versus higher-volume, lower-value procurement through logistics channels.

Vehicle positions show reliance on single-award and limited-distribution contracts. The company operates under a Blanket Purchase Agreement (75N98022A00032) with 193 task orders worth $4 million combined value and an Indefinite Delivery Contract (75N95024D00029) with 66 task orders totaling $7.5 million. A second IDC (75N95023D00018) carries 15 task orders valued at $502 thousand. These vehicles are NIH-centric; 10X Genomics does not compete on government-wide acquisition contracts (GWACs) or multi-agency vehicles. The $7 million NIA IDC and the $800,000 VISN 1 BPA exemplify the single-award, agency-specific model that dominates the company's prime footprint.

Activity has declined from a peak. Award volume reached 203 in 2022, declined to 181 in 2023, fell to 165 in 2024, and contracted to 136 in 2025, with only 9 awards recorded in 2026 (data current through June 15). Over the past five years, 10X Genomics has issued 694 awards out of 1,297 total. Forty-one awards face ultimate completion dates within the next 24 months, representing $1.9 million in combined potential value and therefore recompete exposure. The company's registered federal contractor status dates to July 2015.

Sub-award footprint is minimal. 10X Genomics operates almost exclusively as a prime contractor (1,291 of 1,297 awards, or 100 percent). Two sub-awards appear in the source: delivery of directed energy health research materials to the Johns Hopkins University Applied Physics Laboratory LLC (August 2025) and supplies to the same prime (December 2024), representing less than 0.5 percent of total activity.

The company's positioning reflects specialization in proprietary single-cell and spatial transcriptomics technology: federal customers acquire 10X Genomics products and services primarily through sole-source and brand-name justification procurement, with performance concentrated at the vendor's Pleasanton headquarters and select deliveries to federal research facilities in Bethesda, Baltimore, and other NIH-affiliated locations. No evidence supports competition for federal work outside the life sciences research domain or participation in defense, civilian infrastructure, or grant-funded research enterprise beyond fee-for-service reagent and instrument supply to NIH institutes.